Beyond Cholesterol: New Review Examines 7-Ketocholesterol and Its Role in Disease
A recent review in The Journal of Steroid Biochemistry and Molecular Biology explores how 7-ketocholesterol (7KC) contributes to cellular dysfunction,
Tag: 7-ketocholesterol
Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and
Selective removal of 7-ketocholesterol by a CD-dimer, a novel atherosclerosis therapeutic candidate
The removal of the toxic oxidized cholesterol, 7-ketocholesterol (7KC), from cells through the administration of therapeutics has the potential to
Cyclodextrin derivative developed by Cyclarity in clinical trial
Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX,
Cyclodextrins: Establishing building blocks for AI-driven drug design by determining affinity constants in silico
The effectiveness of cyclodextrins depends on their ability to encapsulate target molecules with strong affinity and specificity, but quantifying affinities
Cyclodextrin dimers against atherosclerosis
7-ketocholesterol (7-oxocholesterol, 7-KC) is the major oxidation product of cholesterol (CHOL), and one of the most toxic metabolites formed when